anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic postsurgical pain (CPSP) is a potential long-term problem following open incisional hernia repair which may affect the quality of life of patients despite successful anatomical repair of the hernia. The aim of this manuscript was to identify the incidence and outcome of patients following open incisional hernia repair in respect of risk factors to develop CPSP.
METHODS: A single-center retrospective analysis of patients who underwent open incisional hernia repair between 2015 and 2021 was performed. Pre-existing conditions (e.g., diabetes mellitus and malignancy), hernia complexity, postoperative complications, and postoperative pain medication were analyzed using the local database. Quality of life and CPSP were assessed using the EuraHS Quality of Life (QoL) questionnaire.
RESULTS: A total of 182 cases were retrospectively included in a detailed analysis based on the complete EuraHS (QoL) questionnaire. During the average follow-up period of 46 months, this long-term follow-up revealed a 54.4% incidence of CPSP and including a rate of 14.8% for severe CPSP (sCPSP) after open incisional hernia surgery. The complexity of the hernia and the demographic variables were not different between the group with and without CPSP. Patients with CPSP reported significantly reduced QoL. The analgesics score which includes the need of pain medication in the initial days after surgery was significantly higher in patients with CPSP than in those without (no CPSP: 2.86 vs. CPSP: 3.35; p = 0.047).
CONCLUSION: The presence of CPSP after open incisional hernia repair represents a frequent and underestimated long-term problem which has been not been recognized to this extent before. CPSP impairs QoL in these patients. Patients at risk to develop CPSP can be identified in the perioperative setting by the need of high doses of pain medication using the analgesics score. Possibly timely adjustment of pain medication, even in the domestic setting, could alleviate the chronicity or severity of CPSP.
This group will consist of 45 pregnant women. The training program based on the motivational interviewing method will continue once a week for a total of 4 weeks.
The present invention relates to a novel system based on lutetium sesquioxide nanoparticles with high purity and crystallinity according to their crystallographic planes obtained by XDR and indexed to crystallographic charts JCPSD No.12-0728 (Lu2O3) of quasi spherical morphology with sizes of up 20nm to 45 nm. Said nanoparticles are radio luminescent by neutron irradiation (177Lu2O3) activation, presenting luminescence emission spectra in the near-infrared region with an emission maximum at ~615 nm, obtaining in vivo optical images of its biodistribution. After functionalization with a prostate-specific membrane antigen (PSMA) inhibitory peptide, lutetium sesquioxide nanoparticles increase their sizes up 30nm to 50 nm, presenting vibration bands corresponding to their functional groups by FT-IR spectroscopy replicated in the absorption bands of the observed UV-Vis spectra. Additionally, the zeta potential values ??in all systems maintain an absolute value higher than 25 mV, which impl ies high stability of the colloidal system. Further, the present invention aims to provide a novel specific nano system (molecular target radiopharmaceutical) with potential application in nanomedicine as a dual imaging agent (optical and nuclear) in vivo and precise molecular target radiotherapy.
Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
Primary cardiac lymphoma (PCL), an extranodal lymphoma involving only the heart (with possible involvement of the pericardium) is a rare entity, accounting for 2% of primary cardiac tumors and 0.5% of extranodal lymphomas. It is more frequent in males; clinical presentation is predominated by cardiac symptoms. The most common histology is Diffuse Large B Cell Lymphoma (DLBCL). Being DLBCL the most frequent histology, patients are usually treated with R-CHOP (rituximab - cyclophosphamide, doxorubicin, vincristine and prednisone) or R-CHOP-like chemoimmunotherapy regimens, with an historically poor outcome, although in the last years survival rates significantly increased. Due to the rarity of this condition, isolated case reports and a few reviews have been published so far, that in most cases included a population collected in a wide period of time, heterogeneously managed both in terms of treatments received and follow-up, and who often did not strictly respect the criteria of PCL. Indeed, while some aspects of PCL are well-known, especially the ones concerning its clinical presentation, a few topics deserve more in-depth analysis. The rationale of this study is to provide an overview on PCL in Italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.
A selective anti-idiotype therapies of cancer, infectious disease or autoimmune disease, allergy or transplantation rejection. Prognostic idiotopes useful in disease diagnosis and/or monitoring are (i) identified and (ii) induced or suppressed by the therapeutic application of modulatory anti-idiotype antibodies, alone or in combination with other immunomodulating agents. Modulatory anti-idiotype antibodies and methods for making and using them in immunotherapy are claimed. 
     Modulatory anti-idiotype antibodies may be made and used in active or passive immunotherapy according to the following method. First, idiotype bearing antibodies (Ab1s) are generated or acquired. Second, select at least one idiotype bearlng Ab1 or T-cell which is reactive with a cancer, infectious agent or autoimmune disease target antigen, allergen or transplant antigen for future screening. Next, make at least one anti-id (Ab2) against the Ab1 or T-­cell receptor. At this point, the anti-ids (Ab2s) made are screened. Each of the anti-ids (Ab2s) may be screened either against the B or T-cell idiotopes of either the sera, blood or tissue of a statistically significant panel of patients or against the serum, blood or tissue of a single patient or animal. In either case, the purpose of the screening is to identify a correlation between idiotope level and either (i) disease presence or progression, or (ii) disease absence or regression. Finally, that anti-id (Ab2) or combination of anti-ids (Ab2s) which induces either (1) suppression of idiotopes which normally fall with disease regression; (2) stimulation of idiotopes which normally rise with disease regression; (3) stimulation of idiotopes which normally fall with disease progression; or (4) suppression of idiotopes which normally rise with disease progression are administered.
Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
OBJECTIVE: Status epilepticus (SE) is a life-threatening prolonged epileptic seizure that affects ~40 per 100 000 people yearly worldwide. The persistence of seizures may lead to excitotoxic processes, neuronal loss, and neuroinflammation, resulting in long-term neurocognitive and functional disabilities. A better understanding of the pathophysiological mechanisms underlying SE consequences is crucial for improving SE management and preventing secondary neuronal injury.
METHODS: We conducted a comprehensive untargeted metabolomic analysis, using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS), on plasma and cerebrospinal fluid (CSF) samples from 78 adult patients with SE and 107 control patients without SE, including 29 with CSF for both groups. The metabolomic fingerprints were compared between patients with SE and controls. Metabolites with differences in relative abundances that could not be attributed to treatment or nutrition provided in the intensive care unit were isolated. Enrichment analysis was performed on these metabolites to identify the most affected pathways.
RESULTS: We identified 76 metabolites in the plasma and 37 in the CSF that exhibited differential expression in patients with SE compared to controls. The enrichment analysis revealed that metabolic dysregulations in patients with SE affected primarily amino acid metabolism (including glutamate, alanine, tryptophan, glycine, and serine metabolism), pyrimidine metabolism, and lipid homeostasis. Specifically, patients with SE had elevated levels of pyruvate, quinolinic acid, and keto butyric acid levels, along with lower levels of arginine, N-acetylaspartylglutamate (NAAG), tryptophan, uracil, and uridine. The tryptophan kynurenine pathway was identified as the most significantly altered in SE, resulting in the overproduction of quinolinic acid, an N-methyl-d-aspartate (NMDA) receptor agonist with pro-inflammatory properties.
SIGNIFICANCE: This study has identified several pathways that may play pivotal roles in SE consequences, such as the tryptophan kynurenine pathway. These findings offer novel perspectives for the development of neuroprotective therapeutics.
This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
Perioperative pain management is an important aspect of quality patient care. Opioid pain medications are increasingly being used for pain control, with the United States writing over 250 million prescriptions for painkillers per year. Increased usage has led to unintended negative consequences for individuals and society. It is estimated that 46 people die each day from an overdose of prescription painkillers, and individual use can lead to the development of tolerance and worse treatment outcomes. Further issues arise when opioids are misused, it is estimated that non-therapeutic use has increased three fold in recent years. In the United States alone in 2006 the estimated total cost of opioid prescription misuse was $53.4 billion, of which $42 billion was attributed to lost productivity, $8.2 billion to criminal justice cost and the remainder drug abuse treatment and medical complications. The federal government has recognized this epidemic and raised a call for clinicians to more responsibly prescribe opiate pain medications.

Opiate use has increased in recent years, from 2000-2010 the use of opiates in office based visits nearly doubled from 11.3% to 19.6% whereas there was no change in the prescribing of non-opioid pharmacotherapies. Further, when specifically looking at new musculoskeletal pain visits, one half resulted in pharmacologic treatment, with the prescribing of non-opioid pharmacotherapies decreasing from 38% to 29% from 2000 to 2010, respectively. The clinical use of opioids for post-operative pain control has also been linked to the opioid epidemic and risk of future abuse. Legitimate opioid use before high school graduation is independently associated with a 33% increased risk of future misuse after high school.

It has been estimated that orthopedic surgeons prescribe 7.7% of all opioids in the United States.Special attention needs to be paid to the amount of opioid pain medications orthopedic surgeons prescribe to patients after ambulatory surgery, there is considerable variability among surgeon and procedure in regards to the amount of opioids to prescribe with many patients left with excess unused medication.An analysis of 250 patients undergoing outpatient upper extremity surgery found that on average patients consumed 10 opioid pills, with 19 pills left over and a total of 4,639 pills going unused in the cohort. Leftover prescription opioids are at risk for diversion to family and friends for nonmedical use. Further studies are needed to quantify the amount of opioids to prescribe for specific orthopedic procedures to limit excess narcotic use, misuse, diversion and contribution to the opioid epidemic.
Initiation of noradrenaline first, up to 0,5 mcg/kg/min. If the patient has MAP \<65 mmHg vasopressin will be started (maximum dose of 0.03 IU/min (2.3ml/h)\]. If If the patient has MAP \<65 mmHg, noradrenaline will be further escalated.
Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
PURPOSE: A pharmaceutical composition containing ibuprofen and arginine as a main component. The composition can be dissolved in water and causes no irritation to the stomach or the oral mucosa and thus exhibits an excellent analgesic effect. It also can be formulated into granules or tablets easily without the use of special binding agents. CONSTITUTION: A pharmaceutical composition contains 30 to 45% by weight of ibuprofen, 30 to 45% by weight of arginine and 9 to 30% by weight of sodium bicarbonate. The mole ratio of ibuprofen and arginine is 0.8 to 1.0, preferably 0.9. During the production of granules, conventional excipients, sweeteners, flavorings or pigments can be added. The single dosage amount of the ibuprofen is 100mg, 200mg, 400mg or 600mg.
Relebactam 250 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
The exercises performed will attend the musculoskeletal dimension of the body, which includes the muscular strength / endurance indexes, which is part of the functional-motor dimension of physical fitness related to health. The protocol will be applied in the form of sessions lasting approximately 50 minutes, performed three times a week on alternate days, for a period of 6 weeks, totaling 20 sessions. For aerobic exercises, a treadmill will be used and for anaerobic exercises, four exercises involving muscle mobility / strength in upper and lower limbs will be performed at weight training station.
<P>PROBLEM TO BE SOLVED: To provide a film preparation rapidly soluble in the oral cavity by combining phenylephrine hydrochloride with hydroxypropyl cellulose and/or hydroxypropyl methylcellulose.  <P>SOLUTION: The rapidly soluble film preparation 1 containing phenylephrine hydrochloride has a resin film 3, one or more shielding layers 5 and one or more drug-containing layers 7. The shielding layer 5 is formed on the resin film 3, contains an edible polymer material and is free from phenylephrine hydrochloride. The drug-containing layer 7 is formed on the shielding layer 5 and contains phenylephrine hydrochloride and at least one kind of substance selected from hydroxypropyl cellulose and hydroxypropyl methylcellulose. The rapidly soluble film preparation 1 containing phenylephrine hydrochloride may optionally have one or more shielding layers 5 containing an edible polymer material and free from phenylephrine hydrochloride on the drug-containing layer 7.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
OBJECTIVE: Anterior temporal lobe resection (ATLR) effectively controls seizures in medically refractory temporal lobe epilepsy but risks significant episodic memory decline. Beyond 1 year postoperatively, the influence of preoperative clinical factors on episodic memory and long-term network plasticity remain underexplored. Ten years post-ATLR, we aimed to determine biomarkers of successful memory network reorganization and establish presurgical features' lasting impact on memory function.
METHODS: Twenty-five ATLR patients (12 left-sided) and 10 healthy controls underwent a memory-encoding functional magnetic resonance imaging paradigm alongside neuropsychometry 10 years postsurgery. Generalized psychophysiological interaction analyses modeled network functional connectivity of words/faces remembered, seeding from the medial temporal lobes (MTLs). Differences in successful memory connectivity were assessed between controls and left/right ATLR. Multivariate regressions and mixed-effect models probed preoperative phenotypes' effects on long-term memory outcomes.
RESULTS: Ten years post-ATLR, lower baseline functioning (verbal and performance intelligence quotient) and a focal memory impairment preoperatively predicted worse long-term memory outcomes. Poorer verbal memory was significantly associated with longer epilepsy duration and earlier onset age. Relative to controls, successful word and face encoding involved increased functional connectivity from both or remnant MTL seeds and contralesional parahippocampus/hippocampus after left/right ATLR. Irrespective of surgical laterality, successful memory encoding correlated with increased MTL-seeded connectivity to frontal (bilateral insula, right anterior cingulate), right parahippocampal, and bilateral fusiform gyri. Ten years postsurgery, better memory performance was correlated with contralateral frontal plasticity, which was disrupted with longer epilepsy duration.
SIGNIFICANCE: Our findings underscore the enduring nature of functional network reorganizations to provide long-term cognitive support. Ten years post-ATLR, successful memory formation featured stronger connections near resected areas and contralateral regions. Preoperative network disruption possibly influenced effectiveness of postoperative plasticity. These findings are crucial for enhancing long-term memory prediction and strategies for lasting memory rehabilitation.
The invention relates to a traditional Chinese medicine epimedium total flavonoid phosphorylation molecular modification method. The invention belongs to the technical field of veterinary drug preparation. According to the invention, epimedium total flavonoid is subjected to phosphorylation molecular modification by using a sodium tripolyphosphate-sodium trimetaphosphate method. With total flavonoid content and phosphate content in the product as indexes, levels of three factors of pH, reaction temperature, and reaction time are researched with an orthogonal design method, and the factors are optimized. Phosphorylated epimedium total flavonoid is prepared under determined optimal modifications of: reaction temperature of 70 DEG C, reaction time of 6h, and reaction pH value of 9. Through infrared spectroscopy, the obtained epimedium total flavonoid phosphorylated compound is epimedium total flavonoid phosphate ester. The contents of total flavonoid and phosphate radical are high, a product yield is high, and the product can be instantly dissolved in water. Safe concentration of liver cell in-vitro culturing is substantially increased. The epimedium total flavonoid phosphate provided by the invention has good water solubility, high yield, and good safety.
PROBLEM TO BE SOLVED: To provide a stable composition, specifically a stable cosmetic composition, which is preferably used for keratin fibers such as hair, with improved color uptake.SOLUTION: The present invention relates to a composition, specifically a cosmetic composition, which is preferably used for keratin fibers such as hair, comprising: (a) at least one oil; (b) at least one nonionic surfactant selected from the group consisting of polyoxyalkylenated fatty alcohols; (c) at least one thickener; and (d) water, where the amount of the (a) oil is 25 mass% or more relative to the total mass of the composition, and the mass ratio of the (a) oil/the (c) thickener is from 25 to 100. The composition according to the present invention can provide improved color uptake. Thus, the keratin fibers treated with the composition according to the present invention can be effectively colored. The composition according to the present invention is stable over time. Therefore, the composition according to the present invention can maintain its aspect for a long period of time. In other words, the aspect of the composition according to the present invention does not substantially change for a long period of time.SELECTED DRAWING: None
INTRODUCTION: The purpose of this protocol is to investigate the risk factors, critical evaluation contents and preventive measures of high-output enterostomy.
METHODS AND ANALYSIS: This scoping review will follow the Joanna Briggs Institute guidelines for scoping reviews. PubMed, EMBASE, CINAHL, the Chinese Biological Literature Database and the Cochrane Library will be searched for relevant literature published from January 2015 to January 2024. The Grading of Recommendations, Assessment, Development and Evaluation and the Risk Of Bias In Non-randomised Studies of Interventions will be used to assess the reliability of the evidence.
ETHICS AND DISSEMINATION: As this scoping review involves database searches for literature analysis, informed consent and ethical approval from patients will not be required. The findings will provide essential decision-making information for researchers, clinicians and ostomy nursing staff. The results of the review will be presented at a scientific conference and published in a peer-reviewed journal.
NEW MATERIAL:A compound expressed by formula I [R is 1-3C alkyl; X is -SOR<1> (R<1> is 1-3C alkyl) or SCN]. EXAMPLE:13-Ethyl-hydroxy-17-methylthiomethyl-gona-4,9,11,-trien-3-one. USE:A remedy for endometriosis capable of suppressing production and release of pituitary gonadotropin [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)]. PREPARATION:A compound expressed by formula II is reacted with ethylene glycol, etc., under acidic condition to form an intermediate product expressed by formula III (Y is ethylene, trimethylene, etc.), which is then reacted with dimethylsulfonium methylide, etc., to provide an intermediate product expressed by formula IV. The resultant intermediate product expressed by formula IV is reacted with metal alkyl sulfide to form an intermediate product expressed by formula V (X' is SR<1>), which is then treated with an acid to eliminate the protecting group of the acetal at the 3-position and give an intermediate product expressed by formula VI. The resultant intermediate product expressed by formula VI is then reacted with an oxidizing agent to oxidize the alkyl sulfide into an alkyl sulfoxide.